Login
Home
Charts
Search
Watchlist
Products

Kerala Ayurveda Ltd

KERALAYUR·BSE
169.50-0.21%Tue, 22 Sept '26 13:58

Kerala Ayurveda Ltd

KERALAYUR
BSE
169.50
-0.21%
|Tue, 22 Sept '26 13:58
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
220Cr
Close
Close Price
169.50
Industry
Industry
Ayurvedic
PE
Price To Earnings
PS
Price To Sales
1.62
Revenue
Revenue
136Cr
Rev Gr TTM
Revenue Growth TTM
11.74%
PAT Gr TTM
PAT Growth TTM
-113.40%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
252632273031312935333533
Growth YoY
Revenue Growth YoY%
4.512.834.415.521.518.3-2.24.214.65.910.916.0
Expenses
ExpensesCr
242527272532413340344237
Operating Profit
Operating ProfitCr
11516-1-10-4-5-2-7-4
OPM
OPM%
2.23.817.02.918.2-3.8-32.4-14.7-14.2-4.6-20.4-11.5
Other Income
Other IncomeCr
10-1010192120
Interest Expense
Interest ExpenseCr
113010213313
Depreciation
DepreciationCr
001021221122
PBT
PBTCr
00003-2-143-7-4-8-8
Tax
TaxCr
0100012100-10
PAT
PATCr
0-1104-3-152-6-5-7-8
Growth YoY
PAT Growth YoY%
-100.028.212.8253.3-241.8-3,000.0341.3-274.3-70.451.9-498.0
NPM
NPM%
0.0-3.01.61.712.0-8.7-49.17.1-18.3-14.0-21.3-24.3
EPS
EPS
0.1-0.80.50.33.1-2.4-12.81.9-7.2-3.8-5.8-6.2
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
252632273031312935333533
Growth YoY
Revenue Growth YoY%
4.512.834.415.521.518.3-2.24.214.65.910.916.0
Expenses
ExpensesCr
242527272532413340344237
Operating Profit
Operating ProfitCr
11516-1-10-4-5-2-7-4
OPM
OPM%
2.23.817.02.918.2-3.8-32.4-14.7-14.2-4.6-20.4-11.5
Other Income
Other IncomeCr
10-1010192120
Interest Expense
Interest ExpenseCr
113010213313
Depreciation
DepreciationCr
001021221122
PBT
PBTCr
00003-2-143-7-4-8-8
Tax
TaxCr
0100012100-10
PAT
PATCr
0-1104-3-152-6-5-7-8
Growth YoY
PAT Growth YoY%
-100.028.212.8253.3-241.8-3,000.0341.3-274.3-70.451.9-498.0
NPM
NPM%
0.0-3.01.61.712.0-8.7-49.17.1-18.3-14.0-21.3-24.3
EPS
EPS
0.1-0.80.50.33.1-2.4-12.81.9-7.2-3.8-5.8-6.2

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4650596277628093103120131136
Growth
Revenue Growth%
17.79.716.85.623.5-19.129.416.310.416.79.011.7
Expenses
ExpensesCr
394351577061719195125149153
Operating Profit
Operating ProfitCr
778571929-5-18-17
OPM
OPM%
15.913.912.98.19.41.211.72.48.3-4.2-13.5-12.8
Other Income
Other IncomeCr
0000001002145
Interest Expense
Interest ExpenseCr
112226756479
Depreciation
DepreciationCr
222111112556
PBT
PBTCr
44435-73-11-12-16-27
Tax
TaxCr
11110-200120-1
PAT
PATCr
33334-520-1-14-16-26
Growth
PAT Growth%
8.819.8-12.2-12.460.6-219.5149.4-117.9-30.9-2,391.8-16.9-113.4
NPM
NPM%
6.06.54.94.15.3-7.83.0-0.5-0.5-11.6-12.4-19.5
EPS
EPS
2.61.70.91.13.8-4.32.60.5-0.5-12.8-13.5-23.1
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4650596277628093103120131136
Growth
Revenue Growth%
17.79.716.85.623.5-19.129.416.310.416.79.011.7
Expenses
ExpensesCr
394351577061719195125149153
Operating Profit
Operating ProfitCr
778571929-5-18-17
OPM
OPM%
15.913.912.98.19.41.211.72.48.3-4.2-13.5-12.8
Other Income
Other IncomeCr
0000001002145
Interest Expense
Interest ExpenseCr
112226756479
Depreciation
DepreciationCr
222111112556
PBT
PBTCr
44435-73-11-12-16-27
Tax
TaxCr
11110-200120-1
PAT
PATCr
33334-520-1-14-16-26
Growth
PAT Growth%
8.819.8-12.2-12.460.6-219.5149.4-117.9-30.9-2,391.8-16.9-113.4
NPM
NPM%
6.06.54.94.15.3-7.83.0-0.5-0.5-11.6-12.4-19.5
EPS
EPS
2.61.70.91.13.8-4.32.60.5-0.5-12.8-13.5-23.1

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1111111111111111121213
Reserves
ReservesCr
-17-4-3-7-3-7-4-57-3-2
Current Liabilities
Current LiabilitiesCr
2448452831426052848899
Non Current Liabilities
Non Current LiabilitiesCr
5424485963674255282824
Total Liabilities
Total LiabilitiesCr
738110392103114110115133129138
Current Assets
Current AssetsCr
1422422833443734564147
Non Current Assets
Non Current AssetsCr
5959616470717381778892
Total Assets
Total AssetsCr
738110392103114110115133129138
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1111111111111111121213
Reserves
ReservesCr
-17-4-3-7-3-7-4-57-3-2
Current Liabilities
Current LiabilitiesCr
2448452831426052848899
Non Current Liabilities
Non Current LiabilitiesCr
5424485963674255282824
Total Liabilities
Total LiabilitiesCr
738110392103114110115133129138
Current Assets
Current AssetsCr
1422422833443734564147
Non Current Assets
Non Current AssetsCr
5959616470717381778892
Total Assets
Total AssetsCr
738110392103114110115133129138

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
64-101257-110-15-24
Investing Cash Flow
Investing Cash FlowCr
-3-3-3-3-4-1-2-70-15-5
Financing Cash Flow
Financing Cash FlowCr
-2017-1216-13-220-932
Net Cash Flow
Net Cash FlowCr
014-2212-16018-193
Free Cash Flow
Free Cash FlowCr
23-161026-34-2-8
CFO To PAT
CFO To PAT%
202.3132.7-352.0487.1123.1-153.3-21.0-2,303.3171.6-34.6147.9
CFO To EBITDA
CFO To EBITDA%
75.661.9-133.4242.969.2991.3-5.3438.3-11.3-96.8136.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
64-101257-110-15-24
Investing Cash Flow
Investing Cash FlowCr
-3-3-3-3-4-1-2-70-15-5
Financing Cash Flow
Financing Cash FlowCr
-2017-1216-13-220-932
Net Cash Flow
Net Cash FlowCr
014-2212-16018-193
Free Cash Flow
Free Cash FlowCr
23-161026-34-2-8
CFO To PAT
CFO To PAT%
202.3132.7-352.0487.1123.1-153.3-21.0-2,303.3171.6-34.6147.9
CFO To EBITDA
CFO To EBITDA%
75.661.9-133.4242.969.2991.3-5.3438.3-11.3-96.8136.0

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5898897139548388314423205220
Price To Earnings
Price To Earnings
21.332.131.628.89.934.9-12.4
Price To Sales
Price To Sales
1.31.91.51.10.50.91.00.92.93.41.61.6
Price To Book
Price To Book
-9.314.111.218.94.915.913.515.816.944.518.419.3
EV To EBITDA
EV To EBITDA
16.921.620.725.213.4149.915.969.943.1-98.2-15.8-17.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
69.666.373.770.373.567.770.567.672.176.7
OPM
OPM%
15.913.912.98.19.41.211.72.48.3-4.2-13.5-12.8
NPM
NPM%
6.06.54.94.15.3-7.83.0-0.5-0.5-11.6-12.4-19.5
ROCE
ROCE%
8.68.57.38.48.4-0.512.35.57.1-10.2-9.8-9.8
ROE
ROE%
-44.147.036.467.751.1-142.339.2-7.7-3.0-147.0-146.8-146.8
ROA
ROA%
3.74.12.82.73.9-4.22.2-0.4-0.4-10.8-11.8-11.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
5898897139548388314423205220
Price To Earnings
Price To Earnings
21.332.131.628.89.934.9-12.4
Price To Sales
Price To Sales
1.31.91.51.10.50.91.00.92.93.41.61.6
Price To Book
Price To Book
-9.314.111.218.94.915.913.515.816.944.518.419.3
EV To EBITDA
EV To EBITDA
16.921.620.725.213.4149.915.969.943.1-98.2-15.8-17.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
69.666.373.770.373.567.770.567.672.176.7
OPM
OPM%
15.913.912.98.19.41.211.72.48.3-4.2-13.5-12.8
NPM
NPM%
6.06.54.94.15.3-7.83.0-0.5-0.5-11.6-12.4-19.5
ROCE
ROCE%
8.68.57.38.48.4-0.512.35.57.1-10.2-9.8-9.8
ROE
ROE%
-44.147.036.467.751.1-142.339.2-7.7-3.0-147.0-146.8-146.8
ROA
ROA%
3.74.12.82.73.9-4.22.2-0.4-0.4-10.8-11.8-11.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Kerala Ayurveda Ltd is one of the oldest publicly listed, full-spectrum Ayurveda companies in the world, with a heritage stretching back roughly 80 years and an ancient lineage of practice going back 5,000. It was a pioneer in taking proprietary Ayurveda products and treatment centres beyond Kerala, and today it operates a “PHYGITAL” (physical plus digital) ecosystem that reaches from soil to soul - growing ingredients, making formulations, running wellness resorts and clinics, and training the next generation of practitioners in the US. The recurring approach is to own the entire chain: it does not just sell Ayurvedic medicine, it manufactures it, administers it in its own retreats, and teaches it in its own academy, so that every part feeds the others. # Business segments Three engines at different stages - a product-manufacturing core that supplies the whole system, a services network of resorts and clinics that delivers the treatments, and a US academy that builds the brand and the practitioner base - each one feeding demand into the others. ## 1. Ayurveda products: the formulations factory that supplies everything else **A range of over 400 classical and proprietary herbal formulations, manufactured in-house, that stock the company’s own clinics and resorts while also selling direct to consumers and doctors across India and the US.** - **Made in its own GMP factories** - the company manufactures at two integrated facilities in Athani and Kotal, with recent investments in a Swiss-imported HPTLC instrument, a blister packing machine, and an extended microbiology lab built to GMP specifications, so quality control stays in-house. - **Proprietary science behind the herbs** - in-house R&D, backed by Katra Phytochem (India), Renovel Discoveries (USA), and Asthagiri Herbal Research Foundation, has produced a US-patented herbal formulation for managing metabolic syndrome (including type 2 diabetes, obesity, and lipid profile) and a Japanese patent for metabolism and weight improvement, giving the company claims on efficacy that generic Ayurveda players cannot make. - **Sold wherever the customer is** - products reach buyers through the company’s own revamped D2C website, Amazon and quick-commerce platforms in India, a Joint Business Plan with Flipkart, 1mg and Nykaa, an eBay partnership covering 190 markets, and a doctor-distribution network across India, so no single channel dominates. - **A premium brand in the works** - the company is developing a new consumer range under a “KERALA AYURVEDA inside” label and a premium brand called “Ru by Kerala Ayurveda” positioned for launch in FY26, aiming to command higher pricing on the back of its safety and efficacy credentials. - **Waste becomes fuel** - herbal waste from both manufacturing units is used as boiler fuel, so the production process carries its own energy offset. ## 2. Wellness resorts and clinics: where the treatments are delivered **A network of owned and partnership-based retreats and day clinics that administer authentic Panchakarma and rejuvenation therapies, turning the company’s own formulations into high-value service experiences.** - **Flagship resort running near-full** - Ayurvedagram in Bengaluru reached 90% occupancy in FY25, with a growing share of Indian guests and a returning foreigner segment boosted by the new Ayush Visa, so the asset is already sweating. - **Bali outpost growing fast** - a 25-room wellness resort in Ubud, Indonesia, operated through a joint venture that the company is restructuring to consolidate revenues, grew 42% in FY24, proving the resort model travels. - **Clinics scaling through partnerships, not just owned real estate** - the company opened 5 new clinics in FY26 and has a doctor-partnership programme called KALPAM that offers treatment-centre and franchise models, supplying partners with products and online visibility while keeping the expansion asset-light. - **Singapore added as a new geography** - a new “SG Clinics” segment, built on a joint venture with Omvedic Singapore, generated Rs.527 lakhs in its first year (FY26), with plans to integrate the revenue fully into KAL. - **Telemedicine extends the reach** - the Kerala Ayurveda DigiApp, launched in late 2020 and built with Medi360, enables remote consultations, secure patient records, and e-commerce medicine delivery, with over 400 doctors enrolled and the Karnataka government’s Ayush directorate connecting its own 100-plus centres to the network. ## 3. US Academy and Wellness Center: the brand-builder that trains the practitioners **The largest vocational Ayurveda institution in the United States, with over 5,000 alumni, which creates a pipeline of practitioners who then recommend and use the company’s products.** - **A credential that carries weight** - the academy offers certified courses of 625 to 2,500 hours, approved by the California State Board of Public and Private Education and recognised by the National Ayurvedic Medical Association (NAMA), so graduates leave with a licence to practise. - **Alumni are a distribution channel** - more than 5,000 trained practitioners have passed through the academy, each one a potential prescriber and advocate for Kerala Ayurveda products in the US market. - **Expanding the classroom footprint** - a branch opened in Norway in 2021 with its first graduating cohort in late 2022, and the company plans further expansion into Canada and Australia, extending the brand’s teaching reach beyond America. - **A second wellness centre on the way** - the US business, which already includes a Wellness Center alongside the academy and product sales, plans to open a second California location in FY27, deepening the services footprint in its strongest overseas market. # Group structure and partners **A listed Indian parent with a web of subsidiaries across the US, Singapore, Indonesia and Europe, held together by a common promoter group and a series of consolidation moves aimed at bringing joint-venture revenues fully onto the balance sheet.** - **Promoter anchors** - the listed entity, Kerala Ayurveda Ltd, sits under a Mauritius-registered holding company, Katra Holdings Limited, with the promoter group entity being Katra Phytochem (India) Pvt Ltd, which has provided loans, trademarks, and business segments to KAL at nil or concessional cost. - **US subsidiaries carry the overseas load** - the American operations run through Ayurvedic Academy Inc. (the academy), Suveda Inc. (products, doing business as Kerala Ayurveda Inc.), Ayu Natural Medicine Clinic, and CMS Katra Holdings LLC with its nursing subsidiary, and in FY20 this cluster generated 22% of consolidated revenue and 70% of net profits. - **Consolidating the joint ventures** - the company is acquiring the remaining 26% of Ayurvedagram Bangalore via a share swap to make it a wholly-owned subsidiary, and is restructuring the Bali joint venture to bring its revenues fully into KAL, so that the resort earnings stop sitting off-balance-sheet. - **Singapore and Europe are the new frontiers** - a 51% stake in Om Vedic Heritage Centre (Singapore) was acquired on 7 August 2024, and Kerala Ayurveda Europe B.V. was incorporated in the Netherlands in December 2025 to import, market and distribute certified products and run an Ayurveda clinic on the continent. - **A legacy dispute resolved** - an insolvency petition filed by Tata Global Beverages (now Tata Consumer Products) in 2021 was mutually settled and the NCLT order was set aside by the Kerala High Court in March 2022, removing a contingent liability from the group’s path.

Documents — Kerala Ayurveda Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/sab927rx3l361q70848ejoa3.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/iiiqhzrjap5vyxqqg5zhcffa.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/u29h6g2lp6qz2nn2y2oozciy.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/sz9yx1ku4oa05471wnx6gnak.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/cd3ca31j5fzevrv3bvbavryr.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/ocqtnm7qtw05ik41eh3gtn23.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/q3cc6gzd9epc8vqpv0uxbnso.pdf
  • Q1 FY2025 Quarterly Result (Jun 2024, PDF): https://www.stockscans.in/document/hgcn1mubul3np5hqys6ff709.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6y3f3wn5j056knol46b636cw.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/6oaoyqe7gvgde6w7oja17tnd.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/t1h5swiaozum4l6qf951vlil.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/oyq6igy4ctv9ji6k1v9lg8y7.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/1zdzlm2h1iuhjoibnazxpmsr.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/xc1cei6d75wxqr3krfi5xdfm.pdf